FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to the recombinant production of human mutant proteins, and can be used to obtain human lipolocalin muteins 2 (hLcn2, hNGAL) at position of 100 amino acid sequence hLcn2, binding to certain targets.
EFFECT: invention enables to obtain human lipolocalin muteins 2, which bind to new ligands which are not characteristic for it, and can serve for binding and exhaustion of pathological forms of natural biological molecules, such as beta-amyloid peptide in Alzheimer's disease, or extrinsomenel B of fibronectin, which is associated with neovascularization of tumour.
18 cl, 28 dwg, 3 tbl, 24 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN LIPOCALIN 2 MUTEINS (Lcn2, hNGAL) WITH TARGETED AFFINITY | 2019 |
|
RU2804336C2 |
| MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) | 2016 |
|
RU2756318C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| PROTEINS SPECIFIC FOR CD137 | 2016 |
|
RU2736312C2 |
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
| NOVEL PROTEINS SPECIFIC FOR ANGIOGENESIS | 2016 |
|
RU2720688C2 |
| AMINOACIL-tRNA SYNTHASE FOR EFFECTIVE INTRODUCTION OF LYSINE DERIVATIVE INTO PROTEIN | 2020 |
|
RU2799794C2 |
| METHODS FOR CELL CULTIVATION AND SETS AND DEVICE FOR THEM | 2016 |
|
RU2761557C2 |
